Cell Therapy News

Immune dysregulation resulting from high tumor burden appeared associated with poor chimeric antigen receptor T-cell expansion and resistance among patients with diffuse large B-cell lymphoma, according to study results published in Blood.

The FDA granted fast track designation to VX-880, a human stem cell-derived therapy for patients with type 1 diabetes, according to the agent’s manufacturer.

The Society for Immunotherapy of Cancer published clinical practice guidelines on the management of toxicities related to the use of immune effector cell therapies, including chimeric antigen receptor T cells.

The FDA granted orphan drug designation to CLBS12, an investigational nongene-edited cell therapy for the treatment of Buerger’s disease, according to the agent’s manufacturer.

The FDA granted accelerated approval to axicabtagene ciloleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release from the agent’s manufacturer.

The FDA cleared an investigational new drug application for NVD-003, a stem cell therapy for treatment of children with congenital pseudarthrosis of the tibia, according to the agent’s manufacturer.

Patients with relapsed or refractory large B-cell lymphoma who received lisocabtagene maraleucel had similar response rates regardless of the type of center providing the chimeric antigen receptor T-cell therapy, according to study results.

Complete responses to idecabtagene vicleucel appeared consistent regardless of age among patients with relapsed or refractory multiple myeloma, according to study results presented at TCT Meetings Digital Experience.

Chimeric antigen receptor T-cell therapy has been heralded as a transformative addition to the cancer treatment armamentarium.

Younger patients who experienced disease progression after CD19-directed chimeric antigen receptor T-cell therapy had significantly shorter OS than those who did not relapse, according to results presented at TCT Meetings Digital Experience.